雌二醇氮芥联合拉司太特化疗对雄激素抵抗性前列腺癌的疗效分析  

Clinical analysis on combined chemotherapy of estramustine and lastet for treating hormone-refractory prostate cancer

作　　者：王阔兴[1] 吴天麟[1] 陈波[1] 王甫剑[1] 张俊杰[1] 韩丛辉[1] 邱祥政[1] 姜波[1] 范涛[1] 

机构地区：[1]徐州市中心医院泌尿外科,江苏徐州221009

出　　处：《现代医药卫生》2011年第16期2407-2408,共2页Journal of Modern Medicine & Health

摘　　要：目的:探讨雌二醇氮芥联合拉司太特化疗对雄激素抵抗性前列腺癌的疗效。方法:选择12例已进行正规内分泌治疗≥3个疗程,病变呈进展趋势的患者,采用雌二醇氮芥与拉司太特联和化疗。结果:经1～3年随访,8例骨转移者治疗后症状均有不同程度缓解,复查骨扫描好转5例(62.5%),稳定3例(37.5%),中位有效期3个月,中位生存期23个月。结论:采用雌二醇氮芥与拉司太特(VP-16)联和化疗可提高患者生存质量及延长生存期。Objective：To investigate the effect of combined chemotherapy of estramustine and lastet for treating hormone-refractory prostate cancer.Methods：12 patients with hormone-refractory prostate cancer,who received at least three courses of regular endocrine treatment and showed progressive trend,were selected and treated with combined chemotherapy of estramustine and lastet.Results：All the cases were followed up for 1-3 years.8 cases of bony metastasis were relieved to some extent after treatment.Reexamination of bone scanning showed improvement in 5 cases（62.5%） and stabilization in 3 cases（37.5%）.The duration of median response was 3 months.The median survival time was 23 months.Conclusion：Combined chemotherapy of estramustine and lastet for treating hormone-refractory prostate cancer could prolong the survival period and improve the quality of life.

关 键 词：前列腺癌 治疗 

分 类 号：R73[医药卫生—肿瘤]